Answers are grounded in this paper and cite their sources.
Clinical case reports scar sarcoidosis diagnosis in a 58-year-old female, suggesting implications for recognition and treatment.
Dear Editor, Scar sarcoidosis is a rare but specific manifestation of cutaneous sarcoidosis, occurring in 2.9% - 29% of overall cases.[1] It is seen in both genders but shows slight female preponderance. A 58-year-old Indian married female presented to us with asymptomatic multiple nodular lesions over the dorsum of right index finger and forehead from the last 1 month. She had a history of trauma over the same sites in an accident 28 years back. There was no history of dyspnoea, night sweats and weight loss. On examination, there were ill-defined nodular lesions over previous scars on dorsum of the right index finger [Figure 1], medial end of right eyebrow and on the centre of her forehead [Figure 2].Figure 1: Lesions over the right index fingerFigure 2: Lesions over the medial end of the right eyebrow and foreheadRoutine laboratory tests, including complete blood count, liver function tests, and renal function tests, were within normal limits. Erythrocyte sedimentation rate (ESR) was 49 mm/hr and serum calcium was 8.6 mg/dl (normal – 7-11 mg/dl). Serological tests showed negative C- Reactive protein (CRP). Serum Angiotensin converting enzyme (ACE) level was 23 U/L. We kept our differentials as granuloma annulare, foreign body granuloma, cutaneous metastasis, hypertrophic scar or keloid. To confirm our diagnosis, we performed a small punch biopsy from the lesion present over the right index finger, which on histopathology showed non-caseating epithelioid cell granuloma [Figure 4]. Chest X-ray was normal. Thus, we made a diagnosis of scar sarcoidosis and ruled out any possibility of systemic sarcoidosis or malignancy.Figure 3: Post-treatment regression of lesionsFigure 4: H/E imagePatient was treated with intralesional injection of triamcinolone 0.5 ml (10 mg/ml) in each lesion on day 1, resulting in partial regression of lesions and then 0.5 ml (5 mg/ml) on day 15. Patient showed complete regression of her lesions 15 days after the second injection [Figure 3]. Scar sarcoidosis can occur as early as six months to as long as 59 years after any injury.[2] Scar sarcoidosis is characterized by the onset of erythematous swelling and the development of papules and nodules within the original scars.[3] These could be scars from surgical incisions, venepuncture, acne, pseudo folliculitis barbae, herpes zoster virus and other forms of skin trauma. The damaged skin sites serve as the foundation for the new concept of Ruocco’s immunocompromised cutaneous district, which refers to a skin area with acquired immune dysregulation that can lead to the local onset of opportunistic disorders such as infections, tumour and granulomatous disorders.[4] Scar sarcoidosis can be associated with long-term disease involving multiple organs but has also been reported in acute forms as well as a sign of recurrence of sarcoidosis in remission.[5] It can be the presenting symptom of systemic sarcoidosis so, whenever there is clinical and histopathologic suspicion of sarcoidosis, a thorough history should be taken along with physical examination and relevant investigations like CBC, LFT, RFT, chest X-ray, serum ACE levels, etc., should be done to rule out systemic involvement. A stepwise approach to patient care is imperative, and potent topical corticosteroids or repeated intralesional injections of triamcinolone (3-10 mg/mL) may be all that is needed in mild skin-limited disease, as we appreciated in our case. The extent of systemic involvement will determine the prognosis but not the extent of cutaneous involvement. A prognosis is usually good in case of minimal or no systemic involvement. Declaration of patient consent The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient(s) has/have given his/her/their consent for his/her/their images and other clinical information to be reported in the journal. The patients understand that their names and initials will not be published and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest.
No takes yet. Share an insight, caveat, or question.
Sharma et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: